Literature DB >> 7829618

A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.

I L Wong1, R S Morris, L Chang, M A Spahn, F Z Stanczyk, R A Lobo.   

Abstract

Enhanced 5 alpha-reductase activity has been found in the skin of the majority of women with hirsutism. Finasteride is a specific competitive inhibitor of 5 alpha-reductase, preferentially inhibiting the type 2 isoenzyme. Therefore, we randomly assigned 14 hirsute women in a 2:1 ratio to 1 of 2 treatment arms: 1) finasteride (F) treatment (n = 9; 5 mg, orally, daily), or 2) spironolactone (S) treatment (n = 5; 100 mg, orally, daily). Each group was treated for 6 months. Patients were evaluated at baseline and after 3 and 6 months of treatment. The 2 groups were similar in age, weight, hip/waist ratio, baseline Ferriman-Gallwey score (F, 19 +/- 2; S, 19 +/- 2), and baseline androgen levels. Finasteride treatment resulted in a significant increase in testosterone (T; P < 0.01) and the T/dihydrotestosterone ratio (P < 0.01). Finasteride caused a significant decrease in 5 alpha-androstane-3 alpha,17 beta-diol glucuronide (3 alpha-diolG; P < 0.05), the 3 alpha-diolG/T ratio (P < 0.01), and the 3 alpha-diolG/androstenedione ratio (P < 0.05). All changes were consistent with 5 alpha-reductase inhibition. In contrast, spironolactone treatment did not result in significant changes in serum hormone levels. Both treatments produced a significant decrease in anagen hair diameters [F, -14.0 +/- 6.7% (P < 0.05); S, -13.4 +/- 3.8% (P < 0.05)] and Ferriman-Gallwey scores [F, -2.1 +/- 0.4 (P < 0.05); S, -2.5 +/- 0.7 (P < 0.05)]. In conclusion, despite significantly different effects on androgen levels, finasteride and spironolactone treatment resulted in a similar clinical effect on hirsutism. Both caused significant, but limited, improvement in hirsutism. Although promising, further studies with finasteride are needed to verify its effectiveness as a treatment for hirsutism. Such studies will also provide a better understanding of the relative contribution of 5 alpha-reductase isoenzymes to hirsutism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829618     DOI: 10.1210/jcem.80.1.7829618

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Clinical application of 5alpha-reductase inhibitors.

Authors:  A Cilotti; G Danza; M Serio
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

Review 2.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

3.  Altered balance between the 5 alpha-reductase and aromatase pathways of androgen metabolism during controlled ovarian hyperstimulation with human menopausal gonadotropins.

Authors:  C C Slater; L Chang; F Z Stanczyk; R J Paulson
Journal:  J Assist Reprod Genet       Date:  2001-10       Impact factor: 3.412

Review 4.  Polycystic ovary syndrome in adolescents: current and future treatment options.

Authors:  George Mastorakos; Irene Lambrinoudaki; George Creatsas
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 5.  Approach to patients with hirsutism.

Authors:  R Sakiyama
Journal:  West J Med       Date:  1996-12

6.  Dutasteride reduces alcohol's sedative effects in men in a human laboratory setting and reduces drinking in the natural environment.

Authors:  Jonathan Covault; Timothy Pond; Richard Feinn; Albert J Arias; Cheryl Oncken; Henry R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2014-02-21       Impact factor: 4.530

Review 7.  Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Authors:  Jason M Hirshburg; Petra A Kelsey; Chelsea A Therrien; A Carlo Gavino; Jason S Reichenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

8.  Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism.

Authors:  Y Sahin; F Bayram; F Keleştimur; I Müderris
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

9.  Effect of finasteride in idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; S Di Marco; F Mantero
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

10.  Sex dependent influence of a functional polymorphism in steroid 5-α-reductase type 2 (SRD5A2) on post-traumatic stress symptoms.

Authors:  Charles F Gillespie; Lynn M Almli; Alicia K Smith; Bekh Bradley; Kimberly Kerley; Daniel F Crain; Kristina B Mercer; Tamara Weiss; Justine Phifer; Yilang Tang; Joseph F Cubells; Elisabeth B Binder; Karen N Conneely; Kerry J Ressler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-03-15       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.